Culbertson A N & Co. Inc. Has $12.15 Million Holdings in McKesson Co. (NYSE:MCK)

Culbertson A N & Co. Inc. lessened its holdings in McKesson Co. (NYSE:MCK) by 0.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 21,316 shares of the company’s stock after selling 188 shares during the quarter. McKesson accounts for approximately 1.9% of Culbertson A N & Co. Inc.’s investment portfolio, making the stock its 12th biggest position. Culbertson A N & Co. Inc.’s holdings in McKesson were worth $12,148,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of the business. MidAtlantic Capital Management Inc. bought a new stake in McKesson during the third quarter worth about $29,000. Wolff Wiese Magana LLC raised its position in McKesson by 742.9% during the third quarter. Wolff Wiese Magana LLC now owns 59 shares of the company’s stock valued at $29,000 after purchasing an additional 52 shares in the last quarter. RPg Family Wealth Advisory LLC bought a new stake in McKesson during the third quarter worth $31,000. ORG Wealth Partners LLC acquired a new stake in shares of McKesson in the 3rd quarter valued at $40,000. Finally, Bruce G. Allen Investments LLC increased its stake in shares of McKesson by 51.9% in the 4th quarter. Bruce G. Allen Investments LLC now owns 82 shares of the company’s stock valued at $47,000 after purchasing an additional 28 shares during the last quarter. Institutional investors own 85.07% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on MCK shares. StockNews.com upgraded McKesson from a “hold” rating to a “buy” rating in a research report on Wednesday, November 6th. Leerink Partners reduced their price target on shares of McKesson from $665.00 to $630.00 and set an “outperform” rating on the stock in a research note on Monday, October 7th. Wells Fargo & Company lifted their price target on shares of McKesson from $535.00 to $641.00 and gave the company an “equal weight” rating in a report on Friday, December 13th. Robert W. Baird raised shares of McKesson from a “neutral” rating to an “outperform” rating and increased their price objective for the company from $531.00 to $688.00 in a research note on Thursday, November 7th. Finally, Mizuho started coverage on shares of McKesson in a research note on Wednesday, December 4th. They set a “neutral” rating and a $630.00 target price on the stock. Two analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $646.14.

Insider Buying and Selling

In related news, EVP Leann B. Smith sold 579 shares of the firm’s stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $572.79, for a total transaction of $331,645.41. Following the completion of the sale, the executive vice president now owns 864 shares of the company’s stock, valued at $494,890.56. This trade represents a 40.12 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 0.11% of the stock is owned by insiders.

McKesson Trading Down 0.4 %

Shares of MCK opened at $592.69 on Tuesday. The company has a market capitalization of $75.24 billion, a PE ratio of 30.69, a PEG ratio of 1.26 and a beta of 0.52. The stock’s 50-day moving average price is $595.11 and its two-hundred day moving average price is $561.01. McKesson Co. has a 12 month low of $464.42 and a 12 month high of $637.51.

McKesson (NYSE:MCK) last posted its quarterly earnings data on Wednesday, November 6th. The company reported $7.07 EPS for the quarter, topping analysts’ consensus estimates of $6.88 by $0.19. The company had revenue of $93.65 billion for the quarter, compared to analyst estimates of $89.33 billion. McKesson had a negative return on equity of 207.50% and a net margin of 0.77%. The firm’s quarterly revenue was up 21.3% on a year-over-year basis. During the same period in the previous year, the firm earned $6.23 earnings per share. Equities research analysts predict that McKesson Co. will post 32.73 EPS for the current fiscal year.

McKesson Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Thursday, January 2nd. Stockholders of record on Monday, December 2nd were given a dividend of $0.71 per share. This represents a $2.84 annualized dividend and a dividend yield of 0.48%. The ex-dividend date was Monday, December 2nd. McKesson’s dividend payout ratio (DPR) is presently 14.71%.

About McKesson

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.